Preclinical perspectives on bisphosphonate renal safety

Oncologist

Volumn 10, Issue SUPPL. 1, 2005, Pages 3-7

  Body, Jean Jacques ^a   Pfister, Thomas ^b   Bauss, Frieder ^c  

^a JULES BORDET INSTITUTE   (Belgium)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Bisphosphonates; Bone metastases; Ibandronate; Preclinical; Renal safety

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; LORON; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ACUTE KIDNEY TUBULE NECROSIS; BONE METASTASIS; CANCER PATIENT; COMORBIDITY; CONFERENCE PAPER; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; KIDNEY BIOPSY; NEPHROTOXICITY; PRIORITY JOURNAL;

EID: 27144538868     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-90001-3     Document Type: Conference Paper

References (39)

1. Body JJ, Mancini I. Bisphosphonates for cancer patients: why, how and when? Support Care Cancer 2002;10:399-407.
2. Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999;9(suppl 2):S66-S80.
3. Corso A, Zappasodi P, Lazzarino M. Urinary proteins and renal dysfunction in patients with multiple myeloma. Biomed Pharmacother 2002;56:139-143.
4. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001;24:19-38.
5. Bauss F, Russell RGG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004;15:423-433.
6. Fleisch H. Bisphosphonates in bone disease: from the laboratory to the patient, 4th ed. New York: Parthenon Publishing Group Ltd., 2000:1-212.
7. Green JR, Seltenmeyer Y, Jaeggi KA et al. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 1997;80:225-230.
8. Troehler U, Bonjour J, Fleisch H. Renal transport of bisphosphonates: accumulation by renal cortical slices enhanced by calcium phosphate ions. J Lab Clin Med 1985;106:23-29.
9. Kino I, Kato Y, Lin JH et al. Renal handling of bisphosphonate alendronate in rats. Biopharm Drug Dispos 1999;20:193-198.
10. Adami S, Zamberlan N. Adverse effects of bisphosphonates: a comparative review. Drug Saf 1996;14:158-170.
11. Cal JC, Daley-Yates PT. Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1,bisphosphonate (APD), in rats and mice. Toxicology 1990;65:179-197.
12. Alden CL, Parker RD, Eastman DF. Development of an acute model for the study of chloromethanediphosphonate nephrotoxicity. Toxicol Pathol 1989;17:27-32.
13. Brazy PC, Gullans SR, Mandel LJ et al. Metabolic requirement for inorganic phosphate by the rat proximal tubule. J Clin Invest 1982;70:53-62.
14. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999;21:389-406.
15. Pfister T, Atzpodien E, Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 2003;191:159-167.
16. Pfister T, Atzpodien E, Bohrmann B et al. Acute nephrotoxicity of three intravenous bisphosphonates in the rat. Basic Clin Pharmacol Toxicol 2005 (in press).
17. Banerjee D, Asif A, Striker L et al. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 2003;41:E18.
18. Lockridge L, Papac RJ, Perazella MA. Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis. Am J Kidney Dis 2002;40:E2.
19. Markowitz GS, Appel GB, Fine PL et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001;12:1164-1172.
20. Markowitz GS, Fine PL, Stack JI et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-289.
21. Rogers MJ, Gordon S, Benford HL et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88(suppl 12):2961-2978.
22. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-2658.
23. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and dysfunctional consequences. Annu Rev Pharmacol Toxicol 1997;37:143-166.
24. Clark EA, King WG, Brugge JS et al. Integrin-mediated signals regulated by members of the rho family of GTPases. J Cell Biol 1998;142:573-586.
25. Ridley AJ, Paterson HF, Johnston CL et al. The small GTP-binding prolein rac regulates growth factor-induced membrane ruffling. Cell 1992;70:401-410.
26. Zhang D, Udagawa N, Nakamura I et al. The small GTP-binding protein, rhop21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci 1995;108:2285-2292.
27. Bauss F, Body JJ. Ibandronate in metastatic bone disease: a review of preclinical data. Anticancer Drugs 2005;16:107-118.
28. Alden CL, Burns JL, Parker RD et al. Characterization of the early ultrastructural and biochemical events occurring in dichloromethane diphosphonate nephrotoxicity. Toxicol Pathol 1990;18:661-666.
29. Geng Z, Monier-Faugere MC, Bauss F et al. Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparachyroid bone changes in mild experimental renal failure. Clin Nephrol 2000;54:45-53.
30. Brkovic D, Seibel M, Juchem R et al. Effect of augmentation cystoplasty on bone metabolism in chronic uremic rats. J Urol 2004;171:921-925.
31. Desikan R, Veksler Y, Raza S et al. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol 2002;119:496-499.
32. Kunin M, Kopolovic J, Avigdor A et al. Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient. Nephrol Dial Transplant 2004;19:723-726.
33. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-1679.
34. Diel I, Body JJ, Bergström B. Renal safety of intravenous (i.v) ibandronate for up to 4 years of treatment in patients with metastatic bone disease. Ann Oncol 2004;15(suppl 3):iii224.
35. Bell R. Efficacy of ibandronate in metastatic bone disease: review of clinical data. The Oncologist 2005;10(suppl 1):8-13.
36. Pfister T. Comparative renal effects of two intravenously administered bisphosphonates. Toxicology 2004;196:169-170.
37. Mancini I, Dumon JC, Body JJ. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 2004;22:3587-3592.
38. Heidenreich A, Ohlmann C, Olbert P et al. High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 2003;1(suppl 5): S270.
39. Ohlmann C, Heidenreich A. Efficacy of ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer. Support Care Cancer 2003;11:396.